linjc16/ctgov huggingface dataset:
Prognostic Value of Each Codon-specific KRAS Mutation in Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
This retrospective study reviewed 3,144 patients who underwent surgery for colorectal cancer. This study was designed to comprehend the clinicopathological characteristics associated with individual codon-specific KRAS mutations in colorectal cancer.

Detailed Description
-----------------
This study was designed to comprehend the clinicopathological characteristics associated with individual codon-specific KRAS mutations in colorectal cancer including codon 12, 13, and 61. Furthermore, the main objective of this study was to determine whether KRAS codon 13 mutation could serve as a prognostic biomarker of colorectal cancer in a relatively large cohort of subjects. Overall survival (OS) and recurrence-free survival (RFS) were calculated from the date of surgery and compared using the Kaplan-Meier method and log-rank test. For analysis of risk factors for tumor recurrence, Cox proportional hazards regression model was used with the covariance input criterion set as < 0.1. Patients were subdivided based on primary tumor location (colon versus rectum), and MSI status (MSS/MSI-low versus MSI-high).

Official Title
-----------------
Does KRAS Codon 13 Mutation Have Prognostic Value in Colorectal Cancer?

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Genetic: Mutation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients underwent surgery for colorectal cancer from January 2009 to December 2019. Exclusion Criteria: incomplete data on KRAS mutation incomplete data on microsatellite instability (MSI) status dual or triple KRAS mutation stage IV
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| KRAS wildtype<br> | |
| KRAS codon 12 mutation<br> | Genetic: Mutation<br> <br> |
| KRAS codon 13 mutation<br> | Genetic: Mutation<br> <br> |
| KRAS codon 61 mutation<br> | Genetic: Mutation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 5-year Recurrence-free survival (RFS) of KRAS wildtype and each codon-specific KRAS mutation |  | from the date of surgery to the event(recurrence and death) up to 5 years | 
| 5-year Overall survival (OS) of KRAS wildtype and each codon-specific KRAS mutation |  | from the date of surgery to the event(death) up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence-related factor |  | Recurrence in 5 years after the date of surgery |
Return on Investment on Lap Gastric Bypass Regarding Quality of Life

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the cost of treatment and adverse efffects therof corresponds to quality of life improvements and expected wheightloss.

Official Title
-----------------
Lap Gastric Bypass and Its Impact on Wheightloss, QoL and Economic Cost

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI > 35 age 18-60 years Exclusion Criteria: Prior bariatric surgery Prior gastric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Significant wheigtloss |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life improvement |  | 3 months and 12 months post surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Bariatric surgery, Laparoscopic gastric bypass, Quality of life, QALY
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.

Official Title
-----------------
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Drug: sumanirole
* Drug: ropinirole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parkinson's disease of less than 7 years duration Modified Hoehn and Yahr Scale Stages 1 through 3. Age greater than or equal to 30 years old. Men or women (women of childbearing potential must have a negative pregnancy test at screen) and both must use adequate contraceptive methods. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: Atypical Parkinson's disease syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases. Levodopa received for 1-year accumulated interval in the last two years. Dopamine agonist medications or catechol-o-methyl transferase inhibitors in the 30 days prior to baseline. Unstable dose regimes of hypnotics, anxiolytics or antidepressants Dementia History of stereotaxic brain surgery, psychosis or active epilepsy within past year. Participation in clinical trial within the previous 30 days. Malignant melanoma or history of melanoma Significant medical or pshychiatric condition.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: sumanirole|nan|
|Drug: ropinirole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in UPDRS (Unified Parkinson's Disease Rating Scale) II + III total scores at end of maintenance, for sumanirole compared to placebo |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety profile of sumanirole; the benefit of sumanirole in quality of life measures, and change from baseline in UPDRS II + III total scores at end of maintenance, for sumanirole compared to ropinirole |  |  |
Nutrition Study of Effect of High Iron Beans on Iron Status

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether beans bred to have a high iron content are effective in improving the iron status of young women.

Detailed Description
-----------------
The goal of the study is to determine the efficacy of biofortified beans in improving the iron status of young women in Rwanda.

Official Title
-----------------
Efficacy of Iron Biofortified Beans in Improving the Iron Status of Rwandan Adolescent Girls: A Randomized Control Trial

Conditions
-----------------
Iron Deficiency

Intervention / Treatment
-----------------
* Other: Biofortified beans
* Other: BEAN


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-pregnant adolescent subjects of reproductive age with low iron stores with or without mild anemia, who are otherwise healthy, will be enrolled in the study Exclusion Criteria: Pregnant, lactating, severe anemia, low BMI would be excluded

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: High iron bean<br>High-iron bean | Other: Biofortified beans<br>* Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration<br>|
| Placebo Comparator: Low iron bean<br>Low-iron bean | Other: BEAN<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improved iron status | Improvement in serum ferritin | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improved physical and cognitive performance | Tests on physical performance using accelerometers and breath tests; cognitive tests | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ferritin
ACT MALI: Treatment of Malaria Based on Combination Therapies

Study Overview
=================
Brief Summary
-----------------
Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated falciparum malaria and malaria attributable anemia

Official Title
-----------------
Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali

Conditions
-----------------
Malaria

Intervention / Treatment
-----------------
* Drug: Artesunate
* Drug: Artesunate + Sulfadoxine-Pyrimethamine
* Drug: arthemether + lumefantrine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body weight > 5kg Residence in the investigator site area for the duration of the trial Axillary temperature ≥ 37,5°C at Day 0 Confirmed Plasmodium falciparum infection,with parasitemia range from 2000 to 200000 asexual parasites /µl of blood Exclusion Criteria: Danger signs or signs of severe malaria Other severe illnesses Allergy to one of the drugs Pregnant women The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment | Drug: Artesunate<br>* oad, per os, 3 days of treatment<br>|
| Active Comparator: 2<br>Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os | Drug: Artesunate + Sulfadoxine-Pyrimethamine<br>* oad, per os<br>|
| Active Comparator: 3<br>Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days | Drug: arthemether + lumefantrine<br>* bid, per os. Duration of treatment: 3 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical and parasitological cure rate |  | at day 28 | 
| Clinical and biological tolerability |  | During the study period |
Treatment for Calcium Phosphate Kidney Stone Disease

Study Overview
=================
Brief Summary
-----------------
The investigators will examine in two studies whether citric acid or potassium citrate can reduce calcium phosphate saturation in urine of Calcium Phosphate stone formers.

Detailed Description
-----------------
We will examine in two short-term placebo-controlled cross-over metabolic studies whether citric acid or potassium citrate can reduce calcium phosphate saturation in urine of CaP stone formers. The first study will be conducted in hypocitraturic CaP stone formers without hypercalciuria, and will compare the effects of potassium citrate, citric acid and placebo. The second study will be conducted in hypercalciuric CaP stone formers on a thiazide diuretic who require potassium supplementation, and will compare the effects of potassium chloride alone, potassium chloride + citric acid, and potassium citrate alone. Physicochemical assays will be applied in addition to computer-based stone risk prediction programs to assess risk of stone recurrence.

Official Title
-----------------
Pharmacological Therapy for Calcium Phosphate Urolithiasis

Conditions
-----------------
Calcium Phosphate Kidney Stones

Intervention / Treatment
-----------------
* Drug: Placebo
* Dietary Supplement: Citric Acid
* Dietary Supplement: Potassium Citrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aim 1 Hypocitraturic CaP stone formers urine citrate <320mg/d elevated pH as 24-hr urine pH above 6.40 >21 years Aim 2 Hypercalciuric CaP stone formers 24hr urine calcium >250mg/d in women and >300mg/d in men prior to indapamide use high pH as >6.40 in the absence of urinary tract infection >21 years

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Placebo tablets twice daily | Drug: Placebo<br>* Matching placebo for both aims.<br>|
| Active Comparator: Citric Acid<br>Citric acid tablets twice daily | Dietary Supplement: Citric Acid<br> <br> |
| Active Comparator: Potassium Citrate<br>Potassium Citrate tablets twice daily | Dietary Supplement: Potassium Citrate<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary calcium phosphate saturation |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
calcium phosphate, urolithiasis, kidney stones, hypercalciuria
Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.

Detailed Description
-----------------
Compared with cyclophosphamide(CTX), to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) in LN-V patients with gross proteinuria.

Official Title
-----------------
Prospective Control Study of TW in the Treatment of LN Type V With Gross Proteinuria

Conditions
-----------------
CTX, Lupus Nephritis, Proteinuria

Intervention / Treatment
-----------------
* Drug: tripterygium glycosides


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SLE patients aging 18-60 years, all of whom comply to the ISN/RPS classification. Urine protein≥3.0g/24h, Alb<30g/L and Scr<1.5mg/dL. All cases are type IV, confirmed by renal biopsy. All patients sign the informed consent and be willing to follow-up on time Exclusion Criteria: Accepted drug therapy, such as CTX MMF CsA FK506 or TW more than 2 weeks in the latest 3 months. Scr level above 1.5mg/dL, lasts more than 3 months. Heart, lung or central nervous systems involved or combined with severe infection. With liver function abnormal, ALT or AST being two times above the normal. Pregnant women or patients still in lactation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: immunosuppressor<br>TW 30mg,q.d.*3 months and reduced into 20mg b.i.d | Drug: tripterygium glycosides<br>* The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.<br>* Other names: TW;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To analyze the clinical effects of tripterygium glycosides (TW) in LN-V patients with gross proteinuria. |  | 48 months |
NRS 2002 as a Predictor of Prognosis in COPD With Respiratory Failure

Study Overview
=================
Brief Summary
-----------------
This is a prospective study of patients diagnosed with chronic obstructive pulmonary disease (COPD) with respiratory failure and admitted in West China Hospital during April 2017 to March 2019. The following variables will be prospectively studied: age, sex, height, weight, respiratory function indicators, arterial blood gas analysis results, biochemical data, nutritional risk screening 2002 (NRS 2002) score, short-term and long-term prognostic outcomes. The purpose of this study is to assess whether NRS 2002 is a useful prognosis predictor in COPD patients with respiratory failure.

Official Title
-----------------
Nutritional Risk Screening 2002 Should be Used to Predict Prognostic Outcomes in Chronic Obstructive Pulmonary Disease With Respiratory Failure

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive, Respiratory Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosis of COPD at West China Hospital during April 2017 to March 2019 Partial pressure of O2 (PaO2) < 60 mmHg and/or partial pressure of CO2 (PaCO2) >50 mmHg Age ≥ 18 years Respiratory rates > 23 bpm Exclusion Criteria: Pregnancy or during lactation Ventilatory dysfunction due to neuromuscular disorders, acute and chronic thromboembolic disease, severe illness in other systems Refused to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NRS 2002 score ≥ 3<br> | |
| NRS 2002 score < 3<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictive value of NRS 2002 in identifying COPD patients with respiratory failure who will have poor prognostic outcomes, in terms of mortality |  | up to 2 years | 
| Predictive value of NRS 2002 in identifying COPD patients with respiratory failure who will have poor prognostic outcomes, in terms of 30-day readmission after discharge |  | up to 2 years | 
| Predictive value of NRS 2002 in identifying COPD patients with respiratory failure who will have poor prognostic outcomes, in terms of length of stay |  | up to 2 years | 
| Predictive value of NRS 2002 in identifying COPD patients with respiratory failure who will have poor prognostic outcomes, in terms of complications |  | up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of Demographics (age, sex) |  | up to 2 years |
DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty

Study Overview
=================
Brief Summary
-----------------
This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a drug used in patients with bleeding disorders. It works by activating molecules in the blood stream called platelets that promote clotting. In the study, participants who are have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive medication. Photographs taken before and shortly after surgery will be evaluated for the amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are not eligible to participate.

Official Title
-----------------
A Prospective Randomized Trial for the Use of DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty.

Conditions
-----------------
Postoperative Ecchymosis

Intervention / Treatment
-----------------
* Drug: DDAVP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing Rhinoplasty where nasal bone osteotomy is necessary Exclusion Criteria: Heart Disease Renal Disease with decreased GFR Liver Disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DDAVP<br>Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation. | Drug: DDAVP<br>* Patients Receiving DDAVP prior to operation<br>* Other names: Desmopressin;|
| No Intervention: No DDAVP<br>Patients Will not receive DDAVP prior to Rhinoplasty | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in Ecchymosis and Swelling | Photographs taken preoperatively at 1 day and 8 days post-operatively will be analyzed for bruising | surgery to 8 days post-operatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Behavior Factors | Looking at the time it takes for patients to feel comfortable wearing makeup, going out in public, and returning to work | Surgery to 3 weeks post-operatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rhinoplasty, Ecchymosis, Edema